TY - THES AU - Fülöp, Tamás TI - Hypersensitivity to polymer-coated nanomedicines : mechanism, prediction and prevention PY - 2023 SN - 9789036554633 DO - 10.3990/1.9789036554633 UR - https://m2.mtmt.hu/api/publication/33606840 ID - 33606840 LA - English DB - MTMT ER - TY - JOUR AU - Li, Y. AU - Jacques, S. AU - Gaikwad, H. AU - Wang, G. AU - Banda, N.K. AU - Holers, V.M. AU - Scheinman, R.I. AU - Tomlinson, S. AU - Moghimi, S.M. AU - Simberg, D. TI - Inhibition of acute complement responses towards bolus-injected nanoparticles using targeted short-circulating regulatory proteins JF - NATURE NANOTECHNOLOGY J2 - NAT NANOTECHNOL PY - 2023 SN - 1748-3387 DO - 10.1038/s41565-023-01514-z UR - https://m2.mtmt.hu/api/publication/34424489 ID - 34424489 N1 - Translational Bio-Nanosciences Laboratory, University of Colorado, Anschutz Medical Campus, Aurora, CO, United States Department of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Anschutz Medical Campus, Aurora, CO, United States Colorado Center for Nanomedicine and Nanosafety, University of Colorado, Anschutz Medical Campus, Aurora, CO, United States Division of Rheumatology, School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, CO, United States Medical University of South Carolina Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, United States Ralph Johnson Veterans Affairs Medical Center, Charleston, SC, United States School of Pharmacy, Newcastle University, Newcastle upon Tyne, United Kingdom Translational and Clinical Research Institute, Faculty of Health and Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom Export Date: 07 December 2023; Correspondence Address: D. Simberg; Translational Bio-Nanosciences Laboratory, University of Colorado Anschutz Medical Campus, Aurora, United States; email: dmitri.simberg@cuanschutz.edu LA - English DB - MTMT ER - TY - JOUR AU - Comparetti, E.J. AU - Lins, P.M.P. AU - Quitiba, J. AU - Zucolotto, V. TI - Cancer cell membrane-derived nanoparticles block the expression of immune checkpoint proteins on cancer cells and coordinate modulatory activity on immunosuppressive macrophages JF - JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A J2 - J BIOMED MATER RES A VL - 110 PY - 2022 IS - 8 SP - 1499 EP - 1511 PG - 13 SN - 1549-3296 DO - 10.1002/jbm.a.37387 UR - https://m2.mtmt.hu/api/publication/32785549 ID - 32785549 LA - English DB - MTMT ER - TY - JOUR AU - Comparetti, E.J. AU - Ferreira, N.N. AU - Ferreira, L.M.B. AU - Kaneno, R. AU - Zucolotto, V. TI - Immunomodulatory properties of nanostructured systems for cancer therapy JF - JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A J2 - J BIOMED MATER RES A VL - 110 PY - 2022 IS - 5 SP - 1166 EP - 1181 PG - 16 SN - 1549-3296 DO - 10.1002/jbm.a.37359 UR - https://m2.mtmt.hu/api/publication/32611937 ID - 32611937 LA - English DB - MTMT ER - TY - JOUR AU - Dobrovolskaia, Marina A. TI - Lessons learned from immunological characterization of nanomaterials at the Nanotechnology Characterization Laboratory JF - FRONTIERS IN IMMUNOLOGY J2 - FRONT IMMUNOL VL - 13 PY - 2022 SN - 1664-3224 DO - 10.3389/fimmu.2022.984252 UR - https://m2.mtmt.hu/api/publication/33187173 ID - 33187173 N1 - Export Date: 30 April 2023 LA - English DB - MTMT ER - TY - JOUR AU - Shi, D. AU - Beasock, D. AU - Fessler, A. AU - Szebeni, János AU - Ljubimova, J.Y. AU - Afonin, K.A. AU - Dobrovolskaia, M.A. TI - To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives JF - ADVANCED DRUG DELIVERY REVIEWS J2 - ADV DRUG DELIV REV VL - 180 PY - 2022 IS - 1 PG - 22 SN - 0169-409X DO - 10.1016/j.addr.2021.114079 UR - https://m2.mtmt.hu/api/publication/32552896 ID - 32552896 N1 - Nanotechnology Characterization Lab, Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, MD, United States University of North Carolina Charlotte, Charlotte, NC, United States Nanomedicine Research and Education Center, Institute of Translational Medicine, Semmelweis University, Budapest, Hungary SeroScience LCC, Budapest, Hungary Department of Nanobiotechnology and Regenerative Medicine, Faculty of Health, Miskolc University, Miskolc, Hungary Terasaki Institute for Biomedical Innovation, Los Angeles, CA, United States Cited By :54 Export Date: 10 April 2023 CODEN: ADDRE Correspondence Address: Dobrovolskaia, M.A.; Nanotechnology Characterization Lab, United States; email: marina@mail.nih.gov LA - English DB - MTMT ER - TY - JOUR AU - Lokerse, W.J.M. AU - Lazarian, A. AU - Kleinhempel, A. AU - Petrini, M. AU - Schwarz, P. AU - Hossann, M. AU - Holdt, L.M. AU - Mailänder, V. AU - Lindner, L.H. TI - Mechanistic investigation of thermosensitive liposome immunogenicity and understanding the drivers for circulation half-life: A polyethylene glycol versus 1,2-dipalmitoyl-sn-glycero-3-phosphodiglycerol study JF - JOURNAL OF CONTROLLED RELEASE J2 - J CONTROL RELEASE VL - 333 PY - 2021 SP - 1 EP - 15 PG - 15 SN - 0168-3659 DO - 10.1016/j.jconrel.2021.03.014 UR - https://m2.mtmt.hu/api/publication/31954633 ID - 31954633 N1 - Department of Medicine III, University Hospital, LMU Munich, Marchioninistrasse 15, Munich, 81377, Germany Max Planck Institute for Polymer Research, University Medicine Mainz, Ackermannweg 10, Mainz, 55128, Germany Institute of Laboratory Medicine, University Hospital, LMU Munich, Marchioninistrasse 15, Munich, 81377, Germany Thermosome GmbH, Am Klopferspitz 19 (IZB), Planegg/Martinsried, 82152, Germany Department of Dermatology, University Medical Center of the Johannes Gutenberg-University Mainz, Langenbeckstrasse 1, Mainz, 55131, Germany Export Date: 7 April 2021 CODEN: JCREE Correspondence Address: Lindner, L.H.; Department of Medicine III, Marchioninistrasse 15, Germany; email: Lars.Lindner@med.uni-muenchen.de LA - English DB - MTMT ER - TY - JOUR AU - Maisha, N. AU - Rubenstein, M. AU - Bieberich, C.J. AU - Lavik, E. TI - Getting to the Core of It All: Nanocapsules to Mitigate Infusion Reactions Can Promote Hemostasis and Be a Platform for Intravenous Therapies JF - NANO LETTERS J2 - NANO LETT VL - 21 PY - 2021 IS - 21 SP - 9069 EP - 9076 PG - 8 SN - 1530-6984 DO - 10.1021/acs.nanolett.1c02746 UR - https://m2.mtmt.hu/api/publication/32502897 ID - 32502897 N1 - Cited By :1 Export Date: 7 April 2023 CODEN: NALEF Correspondence Address: Lavik, E.; University of Maryland Baltimore County, 1000 Hilltop Circle, United States; email: elavik@umbc.edu LA - English DB - MTMT ER - TY - JOUR AU - Milosevits, Gergely AU - Mészáros, Tamás AU - Őrfi, Erik AU - Bakos, Tamás AU - Garami, Miklós AU - Kovács, Gábor AU - Dézsi, László AU - Hamar, Péter AU - Győrffy, Balázs AU - Szabó, András AU - Szénási, Gábor AU - Szebeni, János TI - Complement-mediated hypersensitivity reactions to an amphotericin B-containing lipid complex (Abelcet) in pediatric patients and anesthetized rats: Benefits of slow infusion JF - NANOMEDICINE: NANOTECHNOLOGY BIOLOGY AND MEDICINE J2 - NANOMED: NANOTECHNOL VL - 34 PY - 2021 PG - 7 SN - 1549-9634 DO - 10.1016/j.nano.2021.102366 UR - https://m2.mtmt.hu/api/publication/31864261 ID - 31864261 N1 - * Megosztott szerzőség LA - English DB - MTMT ER - TY - JOUR AU - Onishchenko, N. AU - Tretiakova, D. AU - Vodovozova, E. TI - Spotlight on the protein corona of liposomes JF - ACTA BIOMATERIALIA J2 - ACTA BIOMATER VL - 134 PY - 2021 SP - 57 EP - 78 PG - 22 SN - 1742-7061 DO - 10.1016/j.actbio.2021.07.074 UR - https://m2.mtmt.hu/api/publication/32152029 ID - 32152029 N1 - Export Date: 23 August 2021 Correspondence Address: Onishchenko, N.; Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, ul. Miklukho-Maklaya 16/10, Russian Federation; email: natalia@lipids.ibch.ru Export Date: 26 August 2021 Correspondence Address: Onishchenko, N.; Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, ul. Miklukho-Maklaya 16/10, Russian Federation; email: natalia@lipids.ibch.ru LA - English DB - MTMT ER - TY - JOUR AU - Bedőcs, Péter AU - Szebeni, János TI - The Critical Choice of Animal Models in Nanomedicine Safety Assessment: A Lesson Learned From Hemoglobin-Based Oxygen Carriers JF - FRONTIERS IN IMMUNOLOGY J2 - FRONT IMMUNOL VL - 11 PY - 2020 SN - 1664-3224 DO - 10.3389/fimmu.2020.584966 UR - https://m2.mtmt.hu/api/publication/31661709 ID - 31661709 N1 - Department of Anesthesiology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, United States Defense and Veterans Center for Integrative Pain Management, Rockville, MD, United States Nanomedicine Research and Education Center, Department of Translational Medicine, Semmelweis University, Budapest, Hungary SeroScience Ltd, Budapest, Hungary Department of Nanobiotechnology and Regenerative Medicine, Faculty of Health, University of Miskolc, Miskolc, Hungary Export Date: 12 January 2021 Correspondence Address: Szebeni, J.; Nanomedicine Research and Education Center, Department of Translational Medicine, Semmelweis University, SeroScience Ltd, Department of Nanobiotechnology and Regenerative Medicine, Faculty of Health, University of MiskolcHungary; email: szebeni.janos@med.semmelweis-univ.hu Department of Anesthesiology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, United States Defense and Veterans Center for Integrative Pain Management, Rockville, MD, United States Nanomedicine Research and Education Center, Department of Translational Medicine, Semmelweis University, Budapest, Hungary SeroScience Ltd, Budapest, Hungary Department of Nanobiotechnology and Regenerative Medicine, Faculty of Health, University of Miskolc, Miskolc, Hungary Export Date: 12 February 2021 Correspondence Address: Szebeni, J.; Nanomedicine Research and Education Center, Hungary; email: szebeni.janos@med.semmelweis-univ.hu Correspondence Address: Szebeni, J.; SeroScience LtdHungary; email: szebeni.janos@med.semmelweis-univ.hu Correspondence Address: Szebeni, J.; Department of Nanobiotechnology and Regenerative Medicine, Hungary; email: szebeni.janos@med.semmelweis-univ.hu Department of Anesthesiology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, United States Defense and Veterans Center for Integrative Pain Management, Rockville, MD, United States Nanomedicine Research and Education Center, Department of Translational Medicine, Semmelweis University, Budapest, Hungary SeroScience Ltd, Budapest, Hungary Department of Nanobiotechnology and Regenerative Medicine, Faculty of Health, University of Miskolc, Miskolc, Hungary Export Date: 17 February 2021 Correspondence Address: Szebeni, J.; Nanomedicine Research and Education Center, Hungary; email: szebeni.janos@med.semmelweis-univ.hu Correspondence Address: Szebeni, J.; SeroScience LtdHungary; email: szebeni.janos@med.semmelweis-univ.hu Correspondence Address: Szebeni, J.; Department of Nanobiotechnology and Regenerative Medicine, Hungary; email: szebeni.janos@med.semmelweis-univ.hu AB - Intravenous injection of nanopharmaceuticals can induce severe hypersensitivity reactions (HSRs) resulting in anaphylactoid shock in a small percentage of patients, a phenomenon explicitly reproducible in pigs. However, there is a debate in the literature on whether the pig model of HSRs can be used as a safety test for the prediction of severe adverse reactions in humans. Given the importance of using appropriate animal models for toxicity/safety testing, the choice of the right species and model is a critical decision. In order to facilitate the decision process and to expand the relevant information regarding the pig or no pig dilemma, this review examines an ill-fated clinical development program conducted by Baxter Corporation in the United States 24 years ago, when HemeAssist, an αα (diaspirin) crosslinked hemoglobin-based O2 carrier (HBOC) was tested in trauma patients. The study showed increased mortality in the treatment group relative to controls and had to be stopped. This disappointing result had far-reaching consequences and contributed to the setback in blood substitute research ever since. Importantly, the increased mortality of trauma patients was predicted in pig experiments conducted by US Army scientists, yet they were considered irrelevant to humans. Here we draw attention to that the underlying cause of hemoglobin-induced aggravation of hemorrhagic shock and severe HSRs have a common pathomechanism: cardiovascular distress due to vasoconstrictive effects of hemoglobin (Hb) and reactogenic nanomedicines, manifested, among others, in pulmonary hypertension. The main difference is that in the case of Hb this effect is due to NO-binding, while nanomedicines can trigger the release of proinflammatory mediators. Because of the higher sensitivity of cloven-hoof animals to this kind of cardiopulmonary distress compared to rodents, these reactions can be better reproduced in pigs than in murine or rat models. When deciding on the battery of tests and the appropriate models to identify the potential hazard for nanomedicine-induced severe HSR, the pros and cons of the various species must be considered carefully. LA - English DB - MTMT ER - TY - JOUR AU - Szebeni, János AU - Bawa, Raj TI - Human Clinical Relevance of the Porcine Model of Pseudoallergic Infusion Reactions JF - BIOMEDICINES J2 - BIOMEDICINES VL - 8 PY - 2020 IS - 4 PG - 24 SN - 2227-9059 DO - 10.3390/biomedicines8040082 UR - https://m2.mtmt.hu/api/publication/31279240 ID - 31279240 LA - English DB - MTMT ER -